At a glance
- Originator Fujisawa
- Class Anti-inflammatories; Antiallergics; Antiasthmatics
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 27 Feb 1997 No-Development-Reported for Asthma in Japan (Unknown route)